UNICREDIT BANK/CALL/NOVO-NORDISK B/1000/0.1/18.06.25 | Real-time Bid/Ask 10:36:06 05/07/2024 pm IST | ||
| 1.68 EUR / 1.71 EUR | +4.63% |
|
| Current month | -13.37% | ||
| 1 month | +4.52% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 05/24/05 | 1.68 | +3.70% |
| 04/24/04 | 1.62 | +7.28% |
| 03/24/03 | 1.51 | -15.64% |
| 02/24/02 | 1.79 | -7.73% |
| 01/24/01 | 1.94 | +3.74% |
Delayed Quote Börse Stuttgart
Last update July 05, 2024 at 09:23 pm IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
UniCredit
|
| WKN | HD1HLA |
| ISIN | DE000HD1HLA7 |
| Date issued | 28/12/2023 |
| Strike | 1,000 kr |
| Maturity | 18/06/2025 (348 Days) |
| Parity | 10 : 1 |
| Emission price | 0.68 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 2.06 € |
|---|---|
| Lowest since issue | 0.55 € |
| Spread | 0.03 € |
| Spread % | 1.76% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
970
DKK
Average target price
952.2
DKK
Spread / Average Target
-1.84%
- Stock Market
- Warrants
- Warrant
